{"id":"epicutaneous-immunotherapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Local skin reaction"},{"rate":"0.1-1%","effect":"Systemic allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL2108717","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epicutaneous immunotherapy involves applying small amounts of allergens to the skin to stimulate an immune response, leading to increased tolerance and reduced symptoms in individuals with allergies.","oneSentence":"Allergen exposure to induce immune tolerance","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:51:20.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT07003919","phase":"PHASE3","title":"Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)","status":"RECRUITING","sponsor":"DBV Technologies","startDate":"2025-06-24","conditions":"Allergy, Peanut Allergy","enrollment":480},{"nctId":"NCT05741476","phase":"PHASE3","title":"Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"DBV Technologies","startDate":"2023-02-21","conditions":"Allergy, Peanut","enrollment":600},{"nctId":"NCT05424731","phase":"","title":"Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children","status":"AVAILABLE","sponsor":"DBV Technologies","startDate":"","conditions":"Peanut Allergy","enrollment":""},{"nctId":"NCT02636699","phase":"PHASE3","title":"Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2015-12","conditions":"Peanut Allergy","enrollment":500},{"nctId":"NCT03859700","phase":"PHASE3","title":"Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2018-12-06","conditions":"Peanut Allergy","enrollment":304},{"nctId":"NCT03211247","phase":"PHASE3","title":"Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2017-07-31","conditions":"Peanut Allergy","enrollment":414},{"nctId":"NCT02223182","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2014-11","conditions":"Food Allergy","enrollment":198},{"nctId":"NCT01955109","phase":"PHASE2","title":"Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2013-09","conditions":"Peanut Allergy","enrollment":171},{"nctId":"NCT01675882","phase":"PHASE2","title":"Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2012-08","conditions":"Peanut Allergy","enrollment":221},{"nctId":"NCT04371627","phase":"","title":"Viaskin® Peanut (DBV712) Expanded Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"DBV Technologies","startDate":"","conditions":"Peanut Allergy","enrollment":""},{"nctId":"NCT03035370","phase":"PHASE1","title":"Viaskin Pertussis Vaccine Trial","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2016-09-05","conditions":"Whooping Cough","enrollment":102},{"nctId":"NCT03352726","phase":"PHASE1","title":"A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2017-11-24","conditions":"Peanut Allergy","enrollment":27},{"nctId":"NCT02579876","phase":"PHASE2","title":"Milk Patch for Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2015-10","conditions":"Eosinophilic Esophagitis, Milk Allergy","enrollment":20},{"nctId":"NCT01904604","phase":"PHASE2","title":"Peanut Epicutaneous Phase II Immunotherapy Clinical Trial","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09","conditions":"Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity","enrollment":75},{"nctId":"NCT01197053","phase":"PHASE2","title":"Epicutaneous Immunotherapy in Peanut Allergy in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-08","conditions":"Peanut Allergy","enrollment":60},{"nctId":"NCT01170286","phase":"PHASE1","title":"Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy","status":"COMPLETED","sponsor":"DBV Technologies","startDate":"2010-07","conditions":"Peanut Allergy","enrollment":100},{"nctId":"NCT00719511","phase":"PHASE2","title":"Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2008-02","conditions":"Allergies","enrollment":132},{"nctId":"NCT00777374","phase":"PHASE2","title":"Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2008-10","conditions":"Allergic Rhinoconjunctivitis","enrollment":97},{"nctId":"NCT01175759","phase":"PHASE2","title":"Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss","status":"UNKNOWN","sponsor":"EVE Medical Systems Ltd.","startDate":"2010-06","conditions":"Abortion, Recurrent","enrollment":40},{"nctId":"NCT00866437","phase":"PHASE2","title":"Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel","status":"UNKNOWN","sponsor":"EVE Medical Systems Ltd.","startDate":"2009-04","conditions":"Premenstrual Syndrome","enrollment":40},{"nctId":"NCT00873262","phase":"PHASE2","title":"Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)","status":"UNKNOWN","sponsor":"EVE Medical Systems Ltd.","startDate":"2009-04","conditions":"Premenstrual Syndrome","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":248,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Epicutaneous Immunotherapy","genericName":"Epicutaneous Immunotherapy","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allergen exposure to induce immune tolerance Used for Allergic rhinitis, Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}